Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 3/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9453833 | 0.94 | NPY4R (0.43) | C3AR1GNPATNOD1NPY1RNPY2R | |
| SCHEMBL8721756 | 0.92 | C3AR1 (0.41) | C3AR1GNPATNOD1EPHX2FOLH1 | |
| SCHEMBL16554268 | 0.87 | NPY4R (0.41) | C3AR1NOD1NPY1RNPY2RNPY4R | |
| SCHEMBL2116832 | 0.86 | C3AR1 (0.45) | C3AR1GNPATNOD1EPHX2FOLH1 | |
| SCHEMBL29744957 | 0.86 | C3AR1 (0.45) | C3AR1GNPATNOD1EPHX2FOLH1 | |
| SCHEMBL24961322 | 0.86 | GNPAT (0.45) | C3AR1GNPATNOD1EPHX2FOLH1 | |
| SCHEMBL29476474 | 0.86 | C3AR1 (0.45) | C3AR1GNPATNOD1EPHX2FOLH1 | |
| SCHEMBL187696 | 0.86 | C3AR1 (0.45) | C3AR1GNPATNOD1EPHX2FOLH1 | |
| SCHEMBL4647818 | 0.86 | C3AR1 (0.45) | C3AR1GNPATNOD1EPHX2FOLH1 | |
| SCHEMBL12971304 | 0.85 | C3AR1 (0.43) | C3AR1GNPATNOD1EPHX2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110348-B2 | Methods and compositions for the diagnosis and treatment of schizophrenia | NIH - DEITR | 2012-02-07 | — | — | US | disclosed |
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-20090215877-A1 | Methods and Compositions for the Diagnosis and Treatment of Schizophrenia | NIH - DEITR | 2009-08-27 | — | — | US | disclosed |
| US-6958402-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-6919457-B2 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. (US) | 2004-12-16 | — | — | US | disclosed |
| EP-1467732-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | Pfizer Limited (GB) | 2004-10-20 | — | — | EP | disclosed |
| EP-1467731-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | Pfizer Limited (GB) | 2004-10-20 | — | — | EP | disclosed |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-6713496-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| WO-2003061653-A9 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LTD (GB) | 2003-12-24 | — | — | WO | disclosed |
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
| WO-2003061653-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003061652-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| EP-1311488-A1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | Pfizer Limited (GB) | 2003-05-21 | — | — | EP | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002014285-A1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | C3AR1 30/4885GNPAT 1225/4885NOD1 1688/4885 |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | C3AR1 26/4885GNPAT 1298/4885NOD1 1696/4885 |
| US-20040192668-A1 | 3-(imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | C3AR1 37/4885GNPAT 1245/4885NOD1 1172/4885 |
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | C3AR1 41/4885GNPAT 2150/4885NOD1 1494/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | C3AR1 36/4885GNPAT 2920/4885NOD1 1185/4885 |
| US-20030191107-A1 | 3-(Imidazolyl)-2-aminopropanoic acids | FGB, F2, F11 | C3AR1 37/4885GNPAT 1245/4885NOD1 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.